India · Delayed Price · Currency is INR J. B. Chemicals & Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Q4 FY26 saw a 5% revenue decline due to operational reset post-acquisition, but gross margin improved to 70% and adjusted EBITDA margin to 27%. India branded business grew 8%, while international and CDMO segments faced shipment and execution challenges. Merger with Torrent Pharma is nearing completion.
-
Q3 FY26 saw 11% revenue growth and 22% net profit growth, with gross margins up 200 bps to 69.1%. Domestic and international businesses both outperformed their respective markets, and guidance for margins and growth remains strong for FY26.
-
Q2 FY 2026 saw 8% revenue growth and 19% net profit growth, with gross margin up to 68.2% and strong performance in the domestic and CDMO segments. Guidance for 12%-14% growth in domestic and CDMO businesses is maintained, with margin outlook reaffirmed.
-
Q1 FY26 saw 9% revenue growth, 14% net profit rise, and record 30.2% EBITDA margin, with strong domestic and CDMO performance. Torrent Pharma's acquisition and merger plans mark a major strategic shift, while guidance for margins and growth remains robust.
Fiscal Year 2025
-
Q4 FY2025 saw 10% revenue and 15% net profit growth, with strong domestic and CDMO performance, improved margins, and robust cash flow. EBITDA margin guidance was raised to 27-29%, and key brands and new launches are expected to drive future growth.
-
Q3 FY25 saw 14% revenue growth and 22% net profit growth, led by strong domestic and CDMO performance. Margins remained robust, with a 67.1% gross margin and 28.1% EBITDA margin. Outlook remains positive, with double-digit growth expected in Q4 and continued focus on high-margin segments.
-
Q2 FY25 revenue grew 13% year-over-year to INR 1,001 crore, with domestic business up 22% and international up 3%. Gross margin was 66.2%, and operating EBITDA margin reached 28.4%. CDMO business is set for a strong H2 rebound, and CapEx for FY25 will exceed INR 100 crore.
-
Q1 FY25 revenue rose 12% year-on-year to INR 1,004 crores, with domestic business now 60% of sales and EBITDA margin at 29%. Debt was sharply reduced, and guidance for 26%-28% margins is maintained, with strong growth expected in domestic, CDMO, and international segments.